Clinical Trials Directory

Trials / Completed

CompletedNCT05500534

TELAXMAN - Laser Lithotripsy With Automatic Real-time Stone Recognition

Exploratory Feasibility Study of a Novel Laser System for Endoscopic Disintegration of Urinary Stones With Automatic Real-time Stone Recognition

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
40 (actual)
Sponsor
LISA Laser Products GmbH · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Urolithiasis is an extremely common disease affecting about 12% of the world population with increasing tendency. Urinary stones are sediments that form in the kidney from crystals, such as calcium oxalate. Currently, urological endoscopy with laser lithotripsy represents the leading and most frequently used method for the treatment of urinary stones of different localization, size and composition. Surgical urology, including interventional stone treatment, is highly influenced by technology. With regard to fragmentation properties and effectiveness for all stone types Holmium:yttrium-aluminium-garnet (Ho:YAG) laser lithotripsy has become the standard technology to disintegrate urinary calculi. In addition, other kinds of lasers are emerging, such as the thulium fiber laser (TFL); a new solid-state, diode-pumped laser that may provide urologists with increased options for stone treatment. While urolithiasis treatment in general and laser lithotripsy in specific rarely goes along with major complications, recent studies have shown that there are possible indirect risks to the treatment with lasers, such as thermal damages to the urinary tract even at low-power settings if inadequate irrigation is applied. Sufficient irrigation is mandatory to perform safe Ho:YAG laser lithotripsy. The RevoLix HTL+ automatic real-time stone detection module was developed to overcome these limitations and improve the safety of the patient with regard to potential thermal damages. The objective of this clinical investigation is to assess the feasibility of stone recognition and disintegration with the RevoLix HTL+ in clinical conditions and to identify hypotheses to be used in future clinical investigations.

Conditions

Interventions

TypeNameDescription
DEVICELaser lithotripsy with stone recognitionApplication of Revolix HTL+ which features automatic real-time stone recognition
OTHERLaser lithortripsyStandard laser lithotripsy

Timeline

Start date
2022-09-05
Primary completion
2024-08-13
Completion
2024-08-13
First posted
2022-08-15
Last updated
2024-08-21

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT05500534. Inclusion in this directory is not an endorsement.